"Zepbound: A Promising Treatment for Sleep Apnea and Obesity"

Eli Lilly's weight loss drug Zepbound has shown promise as a treatment for obstructive sleep apnea (OSA) in late-stage clinical trials, with preliminary data indicating its effectiveness in reducing the severity of OSA in patients with obesity. The drug, which imitates gut hormones to reduce food intake and appetite, is being considered for FDA approval and has received "fast track designation" for patients with moderate-to-severe OSA and obesity. The results offer hope for the estimated 80 million OSA patients in the U.S., with potential implications for Medicare coverage and increased use among men.